Series D · Biotech
AdvanCell closes $315m Series D for clinical and manufacturing expansion
Ally Bridge Group leads the upsized financing, with Alpha Wave co-leading and new and existing investors participating.
Financing and next steps
The capital is intended to move ADVC001 toward Phase 3, expand Lead-212 supply and US manufacturing, and advance additional programs. Andrew Lam of Ally Bridge and Nik Economopoulos of Alpha Wave join the board.
The planned capacity is intended to support later-stage development and potential commercial demand; the financing announcement does not establish regulatory approval.
Funding history
Series D · This round$315M